These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 35330989)

  • 1. Application of Baricitinib in Dermatology.
    Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
    J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.
    Montilla AM; Gómez-García F; Gómez-Arias PJ; Gay-Mimbrera J; Hernández-Parada J; Isla-Tejera B; Ruano J
    Dermatol Ther (Heidelb); 2019 Dec; 9(4):655-683. PubMed ID: 31606872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
    Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
    Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
    Muddebihal A; Khurana A; Sardana K
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Role of Baricitinib in Dermatology Practice: All We Need to Know!
    Dogra S; Shah S; Sharma A; Chhabra S; Narang T
    Indian Dermatol Online J; 2023; 14(2):153-162. PubMed ID: 37089829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
    Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
    Drugs Context; 2020; 9():. PubMed ID: 33240390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects.
    Klein B; Treudler R; Simon JC
    J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
    Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
    Sardana K; Bathula S; Khurana A
    Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
    Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
    PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis.
    Koumaki D; Koumaki V; Lagoudaki E; Bertsias G
    Eur J Case Rep Intern Med; 2020; 7(1):001383. PubMed ID: 32015973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata.
    Kołcz K; Żychowska M; Sawińska E; Reich A
    Dermatol Ther (Heidelb); 2023 Mar; 13(3):843-856. PubMed ID: 36639612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.